Oral Fixation Some compounders acknowledge this limitation with GLP-1 pills and are making sublingual products insteadincluding drops that are placed under the tongue
Adam DeVore, MD, FAHA, FACC
IGlarLixi is a fixed-ratio combination of insulin glargine and lixisenatide, containing 100 U/mL of glargine and 33 lg/mL of lixisenatide in a 3-mL prefilled injection pen
They can promote mitochondrial biogenesis (increasing the number and function of mitochondria within cells), increase antioxidant activity, stabilize mitochondrial membranes, assist with ATP production, and modulate cell signaling and protection
One current case involves a confiscated injectable product from Hong Kong branded as Slimming King
Importantly, exogenous GLP-1 receptor agonist treatment suppressed both appetite and weight, opening opportunities for direct translation into the clinical setting